FXTAS Key Molecular Pathways Converge with Other Neurodegenerative Disorders
FXTAS Key Molecular Pathways Converge with Other Neurodegenerative Disorders
批准号:
10609928
负责人:
Reymundo Lozano
金额:
$27.15万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-04-15 至 2027-03-31
关键词:
Academic achievementAgeAlzheimer&aposs DiseaseAreaAtaxiaAutomobile DrivingAutopsyBasic ScienceBiologicalBrainBrain regionC9ORF72CGG repeat expansionCell NucleusCell physiologyCellsChronicClinicalClinical ResearchClinical SciencesClinical ServicesCluster AnalysisCollaborationsComplexData ScienceData SetDegradation PathwayDementiaDepositionDiseaseEnvironmentEukaryotaFMR1FMRPFXTASFacultyFoundationsFragile X SyndromeGene ExpressionGene Expression ProfilingGeneticGenetic DiseasesGenetic Predisposition to DiseaseGenetic studyGoalsHybridsImmunohistochemistryImpaired cognitionIndividualInflammationInflammatoryInstructionLaboratoriesLateralLipidsMacrophageMalignant NeoplasmsMediatingMental DepressionMentorsMentorshipMessenger RNAMetabolicMethodsMicrogliaMolecularMolecular BiologyMotor CortexMusNerve DegenerationNeurodegenerative DisordersNeuronsNeurosciencesParkinson DiseaseParkinsonian DisordersPathogenesisPathologicPathologic ProcessesPathway AnalysisPathway interactionsPeptidesPharmaceutical PreparationsPhenotypePhysiciansPrefrontal CortexProcessProteinsProteomeRNAResearchResearch PersonnelResearch Project GrantsResolutionRoleSamplingScientistSclerosisSignal TransductionSomatic CellSystemTimeTissuesTrainingTranscriptTranscription AlterationTremorTremor/Ataxia SyndromeUbiquitinUbiquitinationWestern BlottingWorkbehavioral disinhibitionbiomarker discoverybrain tissuecareercareer developmentcell typecytokinedifferential expressioneffective therapyexcitatory neuronexcitotoxicitygenome scienceshuman tissueinsightinterdisciplinary approachmedical schoolsmetabotropic glutamate receptor 5mitochondrial dysfunctionneurotoxicnovelpolyglycinepolypeptideprogramsprotein aggregationprotein degradationproteostasisresponsesexsingle nucleus RNA-sequencingskillsstemtherapeutic targettranscriptometranscriptome sequencing
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY/ABSTRACT
THE CANDIDATE. Dr. Lozano is an early career physician-scientist, who has drawn on his academic
achievement and diverse training in clinical and basic science to develop an independent research program.
Through his work, he has developed laboratory skills in genetics and molecular biology, as well as clinical
research which together form the foundations of this ongoing project.
CAREER DEVELOPMENT. Dr. Lozano's overall long-term career goal is to lead a meaningful and sustainable
research program that will allow him to remain a well-established and independent investigator in the area of
Fragile X-related disorders. These goals will be accomplished through intense mentorship (Drs. Alison Goate
(mentor), Bin Zhang (co-mentor), and George Diaz(co-mentor)), meaningful collaborations, and personalized
didactic mechanisms, which are outlined in this application.
INSTITUTIONAL ENVIRONMENT. The Department of Genetics & Genomic Sciences at the Icahn School of
Medicine at Mount Sinai is a hybrid world-class basic science and clinical program that offers a broad-based
program of instruction, research, and clinical services. The faculty are experts in the application of molecular
biology, data science, and somatic cell approaches for the study of genetic diseases. The environment
provided in the department is ideal for the execution of the studies outlined in this application.
RESEARCH PROJECT. There
In
understood.
the
hypothesis
the
in
RNA
transcriptome
mechanisms,
To
with
sclerosis/Frontotemporal
FXTAS
determine
are currently no effective treatments for neurodegenerative disorders (NDDs).
order to develop potential therapeutic targets the underlying biological mechanisms mus be more clearly
Fragile X-associated tremor/ataxia syndrome (FXTAS) ffers an opportunity to gain insights into
pathological mechanisms for an NDD disorder that stems from a defined genetic etiology. The overall
is that protein clearance deficits are exacerbated by polypeptides and mRNA-FMR1 produced from
CGG expansion. This results in neuronal response-driven increases in ubiquitin proteins that are deposited
inclusions, leading to cell dysfuction, reactive inflammatory microglial and eventually neurodegeneration
sequencing (bulk and single nuclei) will be used to qualitatively and quantitatively examine the
in postmortem human tissue. Since NDDs involve complex and intertwined biological
an unbiased and hypothesis-free approach for key molecular pathways discovery will be applied.
identify the converging pathologica l processes in NDDS, the novel FXTAS datasets will be cross-examined
available datasets of Alzheimer's Disease, Parkinson Disease and amyotrophic lateral
ementia . This tudy has the potential to not only identify critical mechanisms driving
pathogenesis that would acilitate the discovery of biomarkers and therapeutic targets but also
pathways most central to disease through a cross-examination approach with other NDDs.
, t
o
.
d s
f
期刊论文(7)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Latent Class Analysis Identifies Distinctive Behavioral Subtypes in Children with Fragile X Syndrome.
潜在类别分析可识别脆性 X 综合征儿童的独特行为亚型。
DOI:
10.1007/s10803-022-05821-7
发表时间:
2024
期刊:
Journal of autism and developmental disorders
影响因子:
3.9
作者:
[Kaufmann,WalterE, Raspa,Melissa, Bann,CarlaM, Gable,JuliaM, Harris,HollyK, Budimirovic,DejanB, Lozano,Reymundo, FORWARDConsortium]
通讯作者:
FORWARDConsortium
DOI:
10.3390/genes14081587
发表时间:
2023-08-05
期刊:
GENES
影响因子:
3.5
作者:
[Lewis, Sivan, Woroch, Amy, Hatch, Mary Kate, Lozano, Reymundo]
通讯作者:
Lozano, Reymundo
DOI:
10.3390/genes13091654
发表时间:
2022-09-15
期刊:
Genes
影响因子:
3.5
作者:
[]
通讯作者:
DOI:
10.3390/genes13091660
发表时间:
2022-09-16
期刊:
Genes
影响因子:
3.5
作者:
[]
通讯作者:
DOI:
10.3390/genes13091666
发表时间:
2022-09-17
期刊:
Genes
影响因子:
3.5
作者:
[]
通讯作者:
共 6 条
FXTAS Key Molecular Pathways Converge with Other Neurodegenerative Disorders
-
批准号:10429040
-
项目类别:
-
资助金额:$27.09万
-
财政年份:2022
-
负责人:Reymundo Lozano
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: